Stem cell chief's exit is long overdue
By Editorial,
Sacramento Bee
| 06. 20. 2009
Palo Alto developer Robert Klein II led the ballot campaign in 2004 to create California's stem cell research institute. He wrote the initiative, ensuring that only he would chair the institute's oversight board, which is charged with handling $3 billion in public money.
For more than four years, this page has detailed how Klein's all-powerful control has not been in the best interest of either taxpayers or the stem cell agency, the California Institute for Regenerative Medicine.
Now it appears that Klein will step down from CIRM at the end of 2010 – more than 18 months away.
Klein is an impassioned, tenacious advocate for stem cell research, but he is precisely the wrong person to head a government science agency. Chairing a 29-member board that is far too large and rife with conflicts of interest, Klein has operated the institute in a smothering manner, with little regard to transparency or lines of authority.
Since 2005, Klein has run off talented scientists, such as former CIRM President Zach Hall. He has helped direct millions of dollars to contracts for law...
Related Articles
By Staff, National Women's Law Center | 08.13.2025
INTRODUCTION
Baby bonuses. Motherhood medals. Fertility tracking. You may have heard of these policy proposals as solutions from the Trump administration to help encourage women to have more children.
Besides falling short of ensuring that people have what they need...
By Zusha Elinson, The Wall Street Journal | 08.12.2025
BERKELEY, Calif.—Tsvi Benson-Tilsen, a mathematician, spent seven years researching how to keep an advanced form of artificial intelligence from destroying humanity before he concluded that stopping it wasn’t possible—at least anytime soon.
Now, he’s turned his considerable brainpower to promoting...
By Cade Metz, The New York Times | 08.04.2025
Image by Mike MacKenzie / CC BY 2.0
In downtown Berkeley, an old hotel has become a temple to the pursuit of artificial intelligence and the future of humanity. Its name is Lighthaven.
Covering much of a city block, this...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...